- Home
- DMAC vs CHMG Comparison
DMAC vs CHMG Comparison
Compare DMAC & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CHMG
- Stock Information
- Founded
- DMAC 2000
- CHMG 1833
- Country
- DMAC United States
- CHMG United States
- Employees
- DMAC N/A
- CHMG N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CHMG Major Banks
- Sector
- DMAC Health Care
- CHMG Finance
- Exchange
- DMAC Nasdaq
- CHMG Nasdaq
- Market Cap
- DMAC 310.1M
- CHMG 250.8M
- IPO Year
- DMAC N/A
- CHMG N/A
- Fundamental
- Price
- DMAC $7.06
- CHMG $50.67
- Analyst Decision
- DMAC Strong Buy
- CHMG Hold
- Analyst Count
- DMAC 3
- CHMG 3
- Target Price
- DMAC $12.33
- CHMG $56.33
- AVG Volume (30 Days)
- DMAC 262.5K
- CHMG 5.9K
- Earning Date
- DMAC 11-12-2025
- CHMG 10-21-2025
- Dividend Yield
- DMAC N/A
- CHMG 2.68%
- EPS Growth
- DMAC N/A
- CHMG N/A
- EPS
- DMAC N/A
- CHMG 2.77
- Revenue
- DMAC N/A
- CHMG $86,610,000.00
- Revenue This Year
- DMAC N/A
- CHMG N/A
- Revenue Next Year
- DMAC N/A
- CHMG $32.65
- P/E Ratio
- DMAC N/A
- CHMG $18.30
- Revenue Growth
- DMAC N/A
- CHMG N/A
- 52 Week Low
- DMAC $3.19
- CHMG $40.71
- 52 Week High
- DMAC $7.49
- CHMG $55.73
- Technical
- Relative Strength Index (RSI)
- DMAC 57.38
- CHMG 41.88
- Support Level
- DMAC $6.64
- CHMG $51.06
- Resistance Level
- DMAC $7.13
- CHMG $53.58
- Average True Range (ATR)
- DMAC 0.27
- CHMG 0.93
- MACD
- DMAC -0.00
- CHMG -0.06
- Stochastic Oscillator
- DMAC 77.21
- CHMG 22.61
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About CHMG Chemung Financial Corp
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.